
Sign up to save your podcasts
Or


This podcast discusses new data pertaining to the class of SGLT2 inhibitors in the treatment of diabetes and its cardioprotective properties. As the incidence of type 2 diabetes mellitus rises in the United States, understanding the results of the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial will help prepare you to better treat your patients.
By American College of Cardiology4.4
3737 ratings
This podcast discusses new data pertaining to the class of SGLT2 inhibitors in the treatment of diabetes and its cardioprotective properties. As the incidence of type 2 diabetes mellitus rises in the United States, understanding the results of the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial will help prepare you to better treat your patients.

317 Listeners

505 Listeners

162 Listeners

39 Listeners

897 Listeners

19 Listeners

2 Listeners

3,365 Listeners

136 Listeners

1,154 Listeners

65 Listeners

376 Listeners

17 Listeners

440 Listeners

33 Listeners